Format

Send to

Choose Destination
Hum Genet. 1998 Jan;102(1):57-62.

Molecular screening of Batten disease: identification of a missense mutation (E295K) in the CLN3 gene.

Author information

1
Department of Human Genetics, New York State Institute for Basic Research, Staten Island 10314, USA. OMRDDZHONG@AOL.COM

Abstract

Batten disease, the juvenile form of neuronal ceroid lipofuscinosis, is a prevalent neuron degenerative disorder of childhood. A 1.02-kb genomic deletion in the Batten disease gene CLN3 has been determined to be a common mutation. We developed a PCR method to screen for this deletion and tested 43 Batten disease probands. We found 36% (31/86) of Batten disease chromosomes did not carry the 1.02-kb deletion. Of the three heterozygotes for the 1.02-kb deletion, a novel G-to-A missense mutation at nucleotide 1020 of the CLN3 cDNA sequence was found on two of the non-1.02-kb deletion chromosomes. The missense mutation resulted in a substitution of glutamic acid (E) by lysine (K) at position 295 (E295 K). The E295 K mutation causes a change in predicted local protein conformation. This glutamic acid is a highly conserved acidic amino acid, being present in human, mouse, dog and yeast, which suggests it may play an important role in the function of the Batten disease protein.

PMID:
9490299
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center